Introduction or background: The incidence of chronic lung disease is increasing worldwide due to the spread of risk factors and ageing population. An important advance in treatment would be the development of a bioartificial lung where the blood-gas exchange surface is manufactured from a synthetic or natural scaffold material that is seeded with the appropriate stem or progenitor cells to mimic the functional tissue of the natural lung.
Introduction
The incidence of chronic obstructive pulmonary disease (COPD) across the world is predicted to increase over the coming years. 1 This is particularly the case within the developing world due to increasing rates of tobacco smoking and demographic changes leading to increased exposure to irritants arising from mining, agriculture and urbanization. There is an eminent need to develop new and more effective therapies to treat end-stage lung failure due to COPD and other pulmonary diseases such as pulmonary fibrosis, pulmonary hypertension and cystic fibrosis. Current treatment options for patients with acute end-stage lung failure are limited mainly to mechanical ventilation and extracorporeal membrane oxygenation (ECMO). Mechanical ventilation carries the risk of damage due to airway overextension and overcompression, and of atrophication of respiratory muscles. An ECMO device can only give partial respiratory support because of the low blood volumes that can be bypassed externally. These treatments can avert the death of the patient, but are generally used only temporarily until lung transplantation is possible. However, the possibility of receiving a lung transplant is often limited due to the lack of a suitable matching donor organ, and recipients face the prospect of a life time of immunosuppression therapy.
Fortunately, recent developments in the field of tissue engineering and regenerative medicine have paved the way for new alternative therapies. Landmark achievements in the field have been the development of successful transplantation procedures using tissue-engineered tracheas. 2, 3 These are created using a scaffold, comprising either a decellularized donor organ 2 or an artificial material 3 to serve as the extra-cellular matrix (ECM) of the trachea. To reconstitute its cellular components the scaffold is seeded with the patients' own cells ex vivo using a specialized bioreactor, and then implanted into the patient. The resounding success of the bioartificial trachea has opened up the possibility that eventually it will be possible, using similar techniques, to engineer functional lung tissue on demand for any patient. 4, 5 However, because of the more complex architecture of the lung when compared with the trachea much work needs to be done. The ability to seed a lung scaffold with the correct numbers of the diverse cell types typical of the native lung, in particular epithelial cells (EPCs) and endothelial cells (ECs), represents a significant challenge. This review explains how previous and current research in lung tissue engineering and related fields will contribute to achievement of the final goal of a bioartificial lung. Four key areas of research that will be described are (i) reconstruction of the lung architecture and biomaterials, (ii) application of stem cell technologies, (iii) seeding methods and (iv) mathematical and computational modelling approaches. It will be shown that ultimate success will require the concerted efforts of researchers drawn from a broad range of disciplines, including clinicians, cell biologists, materials scientists and engineers.
Engineering the macro-and micro-architecture of the bioartificial lung Central to the successful creation of the bioartificial lung is the engineering of its internal surfaces, where the vital function of gas exchange between the blood and air takes place. In the human lung this surface comprises the alveolar and vessel walls, which are perfused with air and blood via the extensive branching networks of the bronchiole tree and pulmonary vasculature. A normal adult lung contains 300-500 million alveoli with a total surface area of around 100 m 2 . 6 Moreover, the alveolar wall is ∼0.5 μm thick, and the pulmonary vessels can be as small as 5 μm in diameter (Fig. 1a) . It is a seemingly insurmountable challenge to reproduce the complex multi-scaled architecture of the ECM of a human lung for the purpose of seeding with cells.
Most progress to date on producing lung scaffolds has concerned the decellularization of excised lungs 7, 8 which are perfused with detergents and enzymes to remove all the cellular components of the tissue. This approach produces a scaffold with the correct architecture and ensures that the ECM is non-immunogenic when it is implanted. Because each procedure requires pre-existing native lung tissue it cannot solve the problem of human donor shortage. Hence, the widespread clinical use of biological scaffolds will require the use of xenogenic (animal) scaffolds. 9 The alternative is to develop a bioartificial lung with an air-blood interface that is made from synthetic materials. A form of artificial gas exchange interface already exists in the ECMO machines which since the 1950s have been used for respiratory support during cardiac surgery and critical care. 10 The membrane oxygenator component of these devices typically takes the form of a bundle of porous hollow fibres. Venous blood is pumped across the outer surfaces of the fibres, while oxygen-rich gas is pumped through the fibre lumens (Fig. 1b) . Current manufacturing technology places lower limits on the thickness and diameter of the fibres that can be produced. Hence, the intramural diffusion rates, and the area of the gas exchange surface, are significantly lower than in the native lung. For this reason pumps are required to increase the gas exchange rate. Also because the artificial polymers used in the fibres are thrombogenic, ECMO devices have a limited usable lifetime due to clot formation on the fibre surface. Recent work has been to improve the performance of ECMO devices by coating the gas exchange surface with EPCs 11 and ECs 12 to mimic the native pulmonary vasculature. A particular aim is to harness the anti-thrombogenic properties of ECs (Fig. 2a ) so as to increase the lifetime of ECMO devices without the need for administering anticoagulants to the patient. Moreover, attempts are being made to produce miniaturized ECMO devices, 13, 14 which are wearable ( Fig. 2b) , so that the patient can experience the benefits of mobility and exercise. These developments will produce a 'wearable bioartificial lung' which, by allowing longer term support prior to implantation, will represent a significant advance in patient care. It should be noted that the performance capacity of the healthy human lung is far in excess of that required to perform basic daily activities. Nevertheless to create an artificial scaffold for a bioartificial lung with sufficient gas exchange area will require the further development of precision manufacturing technologies. A promising development is the use of 15 and micromilling technologies 16 to create molds for miniaturized pulmonary networks. Advances in 3D-rapid prototyping techniques and ink-jet printing will see the advent of the 'organ printer' 17 which, using data obtained from high-resolution micro-tomography (μCT) images of lungs, will be capable of rendering the alveolar and microvascular structures from polymeric materials. So-called 'bioprinters' based on ink-jet 18 and laser 19 printing technologies may eventually be able to deposit cells and ECM simultaneously to create a seeded lung scaffold, 20 although current prototypes are not capable of rendering cell monolayers.
Biomaterials for the bioartificial lung
Of fundamental importance is the nature and composition of the scaffold material used to fabricate the bioartificial lung 21 (Table 1) . Xenogenic scaffolds for use in the bioartificial lung can be obtained by decellularizing the lungs of pigs. Decellularized porcine tissue has already found widespread clinical use in heart valves and vascular stents, but to ensure porcine lung scaffolds are nonimmunogenic and pose no risk of zoonoses transmission requires extensive decellularization and rigorous testing of the donor tissue prior to implantation. As well as providing cells with an ECM whose structure closely matches with that of native tissue, biological scaffolds may also retain a diverse set of proteins that can stimulate the proliferation of seeded cells and serve as chemoattractants for host cells. Alternatively, artificial scaffolds have the advantage of being non-immunogenic and in principle could be produced rapidly to meet the specific needs of a patient, with superior material properties to that of decellularized tissue. The material chosen must be biocompatible, i.e. non-toxic, chemically stable and not cause an adverse reaction when implanted. It is likely that the best choices for artificial materials will be those whose biochemical and biomechanical properties, and micro and nanoscale structure, mimics that of the native ECM.
A challenge to the successful development of the wearable bioartificial lung is that the hydrophobic nature of the polymers typically used to make the hollow fibres in ECMO devices, e.g. silicone, restricts the degree of cell adhesion. Surface modification through physiochemical and/or chemical treatment is needed to guarantee uniform cell attachment 22 and to create a cell monolayer that is resistant to high fluid shear stress due to the blood flow.
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Electrospun scaffolds of pure polyethylene terephthalate (PET) or nanocomposites of PET and polyurethane (PU) fibres have been successfully used for making tracheal scaffolds in part because they closely replicate the fibrous nanoscale structures formed by collagen and elastic fibres in the native tracheal wall (Fig. 3) . However, because electrospinning involves the depositing of layers of fibres onto a surface, only simple structures such as mats and tubes can be produced. It is likely that mouldable substances including synthetic hydrogels 23 such as poly(ethylene glycol) (PEG) and poly(vinyl alcohol) (PVA), and synthetic elastomers 24 such as poly (glycerol sebacate) (PGS), 25 will be needed to reproduce the more complex architecture of the native lung. The scaffold must have sufficient pore size and interconnectivity to allow for the transfer of dissolved gases across the interstitium. 26 Although the permeability of the material to liquids must not be so great as to risk flooding of the airway, interstitial fluid is essential for providing aqueous diffusion of nutrients to the EPCs on the alveolar surface and for permitting chemical signalling between the EPCs and ECs that is part of normal lung physiology. 27 The porosity and substrate properties of the material should also permit the infiltration and migration of circulating host cells. As well as being the correct density to ensure that the bioartificial lung has the appropriate weight, the elastic properties of the scaffold material need to be such that the lung can be deformed by the diaphragm with the correct amount of force. Furthermore, the material must be capable of undergoing many repeated cycles of large deformation without loss of integrity and mechanical properties.
Biodegradable materials, such as poly-lactic acid (PLA) and PU, could be used in the bioartificial lung to allow interstitial fibroblasts to remodel the scaffold in the event of injury, or to allow the lung to grow if it is implanted into juvenile patients. However, the rate and manner of the degradation of the artificial ECM, and its replacement with natural ECM, must be such that the integrity and function of the implant is not compromised.
With regard to making specific choices for artificial materials used to construct the bioartificial lung, much will be gained from the analysis of decellularized tissue 28 since the most appropriate materials are likely to be those whose composition and structure match closely to those of native lung ECM. That the nature of cell-ECM interactions is central to tissue engineering is evidenced by the vast amount of research carried out in the field of biomaterials. 29 However, given the exact requirements described here for materials appropriate for lung tissue engineering, further developments in the field are required before artificial lung scaffolds can be approved for clinical use.
Cell types and reconstituting lung functionality
The bioartificial lung must perform adequately and remain viable after implantation when the scaffold is seeded with the appropriate types of cells in sufficient numbers. The two most important cell types are EPCs to line the airway lumina and ECs to line the pulmonary vasculature. The EPCs provide mucociliary clearance of the airways while the ECs downregulate the thrombogenic response of blood platelets to the ECM. Important signalling pathways exist between the EPCs and ECs, such as those that regulate the amount of interstitial fluid, thereby preventing pulmonary oedema in the native lung. 27 There are other diverse types of cells present in the native lung, which contribute both to its proper function and its pathology. Alveolar macrophages play an important role in lung clearance while myofibroblasts contribute to healing of the epithelium. Smooth muscle cells, and their accompanying nerve fibres, regulate blood vessel and bronchiole diameter. Lymphatic vessels in the interstitium serve as a conduit for immune cells and drains interstitial fluid. The lung has its own resident population of stem cells providing self-renewal in response to injury. 30, 31 Lung cell phenotype varies with spatial position within the lung; EPCs exist as ciliated cells in the upper airway but as type I and II pneumocytes in the alveoli. Instead of directly reseeding the scaffold with the full diversity of cell types, a possible alternative approach is to harness the body's own repair mechanisms to deliver these cells, with their correct spatial organization, into the scaffold after implantation. The blood contains circulating bone-marrow derived cells such as fibrocytes, and endothelial and epithelial progenitor cells, which home to the lung in the case of injury. To enhance this natural regeneration a possible approach, used for the bioartificial trachea, 3 is to seed the scaffold prior to implantation with bone marrow aspirate taken from the patient. This might work by ensuring rapid delivery of the required progenitor cell types, enhancement of the homing of host cells and, due to the presence of mononuclear cells (MNCs), the dampening down of inflammation after implantation. It is speculative on the part of the authors that this method will succeed. Indeed, it is as yet not clear whether bone marrow contains sufficient numbers of progenitor cells to enhance regeneration. Exogenous growth factors such as vascular endothelial growth factor applied directly into the thoracic incision, or incorporated into the scaffold material, 32 may also be a means of enhancing homing, infiltration and attachment of host cells to the implant. The means by which progenitor and stem cells regenerate the airway is presently not understood. An important requirement is believed to be that cells should be presented with the correct biophysical and biochemical environment by the scaffold. Important lessons will come from studies of the reseeding of decellularized lungs 8, 33, 34 and in vitro studies that replicate the function of the lung interstitium will also prove valuable. 35, 36 Because it is permissible for the bioartificial lung to have lower performance than a healthy native lung, it may not be necessary to seed the scaffold with the full diversity and number of lung cells. Also the nature of the architecture and biomaterials chosen for the ECM may dictate the types of cells required. In the wearable bioartificial lung, EPCs are not needed to line the lumens of the hollow fibres because the low permeability of the fibre walls prevents the entry of air borne pathogens. Reducing cell diversity could actually improve the performance of the bioartifical lung; without smooth muscle cells in the interstitial and vascular walls there is reduced risk of pulmonary hypertension and asthma.
Given that the minimum requirements for seeding of the bioartificial lung should be EPCs and ECs, an important question arises as to the source of these cells (Table 1) . In a normal adult lung there are in the order of 100 billion EPCs lining the airway. Harvesting small numbers of the patient cells from lung biopsies is difficult, and expanding them in vitro to such vast numbers may be too impractical. A possible alternative is to expand and differentiate mesenchymal stem cells (MSCs), which can be readily obtained from the patients' bone marrow. Some studies suggest MSCs can be differentiated into EPCs 37 and ECs 38 in vitro but the results are controversial. 39 Human embryonic stem cells (hESCs) are capable of being differentiated into EC 40 and EPC 41 lineages in vitro and can divide an unlimited number of times. Eventually, it may be possible to develop a perpetual source of hESCs within an industrialized cell bank from which the required number of cells can be drawn, thereby circumventing the need for the expansion of the patients' own cells. A limited number of clinical trials involving hESCs have been performed, 42 although there are still impediments to their clinical use arising from ethical, legal and religious concerns. 43 There are also the disadvantages that hESCs and cells differentiated from them are potentially tumourigenic, and their non-autologous origin may render them immunogenic to the patient. Induced pluripotent stem cells (iPSCs), derived from the patients' own cells, also hold great promise for use in the bioartificial lung since they have the pluripotent qualities of hESCs without immunogenicity. The risk of iPSCs and differentiated iPSCs being tumourigenic remains a concern for their clinical use. Before stem cell technology can be used effectively to produce EPCs and ECs for the bioartificial lung, further research is needed to optimize the production of differentiated cells. Current protocols use a combination of growth factor induction and cell sorting that produces a yield of differentiated cells that is typically very low. The fundamental difficulty lies with an incomplete understanding of the complex gene regulatory networks governing stem cell differentiation. For example, the importance for cell differentiation of the mechanical forces acting on cells is only beginning to be uncovered. 44 It is hoped that such research will eventually lead to improved cell yields and differentiation specificity required for the bioartificial lung.
Cell seeding and bioreactors
Prior to implantation the bioartificial lung must be seeded with EPCs and ECs using techniques capable of delivering cells through the full extent of the bronchiole and vascular networks, while ensuring that the cells are able to attach to the lumenal walls. Ideally, the number of cells used should be to achieve uniform coverage of the lumenal surfaces. Alternatively, a subconfluent layer of cells could be seeded and then allowed to expanded to full confluency in the bioreactor or after implantation.
The method for seeding will likely involve perfusion of a suspension of EPCs through the trachea, and ECs through the pulmonary artery and vein of the scaffold (Fig. 4) . A constant fluid flow through the pulmonary vasculature should be sufficient to seed the ECs onto the vessel walls; however, since the ends of the bronchiole tree are closed it may be necessary to apply a negative pressure gradient across the interstitium to draw EPCs onto the alveolar walls. Because attachment of cells to biomaterial surfaces is initially weak, the perfusion must be performed gently to avoid cell detachment due to fluid shear stress. 45 Care must also be taken to avoid preferential deposition of cells proximally to their point of injection into the lumina.
After seeding, the scaffold should be incubated for an appropriate length of time to further enhance attachment, proliferation and differentiation of cells. This should involve oscillatory ventilation of the airway and perfusion of the pulmonary vasculature with media or even a sample of the patients' blood. As well as presenting the seeded cells with sufficient nutrients, natural mechanical strain conditions 46 and biochemical milieu, this will allow the gas exchange performance of the organ to be assessed prior to implantation. Further improvements are required to improve the reseeding of decellularized lung tissue, which currently is only capable of producing grafts with limited gas exchange and viability. 8, 34 Attempts to seed the hollow fibres of the wearable bioartificial lung with ECs will also provide clues for addressing the additional challenge of seeding artificial polymeric scaffolds.
Mathematical and computational modelling for the bioartificial lung
Mathematical and computational modelling should prove valuable for developing the bioartificial lung by allowing theoretical predictions to be made of the effects of using different experimental conditions on the outcome of the seeding, incubation and postimplantation performance. In its simplest instance, mathematics can be used to calculate the number of cells required to seed a lung scaffold based on its surface area and the area of attached cells and their division rate.
Computational modelling can be used to simulate the attachment of cells during perfusion seeding of the scaffold, thereby predicting experimental flow rates that give optimal cell surface coverage. Central to such studies are computational fluid dynamics (CFD) simulations of the complex flow of the perfusion media as it drives cells through the scaffold lumina. CFD modelling is essential for estimating the Fig. 4 Schematic diagram showing the process and apparatus for seeding and incubation of a bioartificial lung fluid shear stress experienced by cells in such flows because it cannot be measured experimentally. A closely related application is in the design of the wearable bioartificial lung, where CFD modelling can be used to calculate the shear stress arising from the blood flow, which acts on the blood platelets and the ECs seeded onto the hollow fibres (Fig. 2a) . These calculations are performed to ensure that the shear stress levels remain within normal physiological levels.
Mathematical modelling can also be used to predict the gas exchange of the bioartificial lung taking into consideration the details of the architecture and the permeability characteristics of the ECM. Such models are a valulable tool for the optimization of the performance of miniaturized ECMO devices. 47, 48 In the case of the implantable bioartificial lung these models need to be vastly extended to account for inflation and deflation of the parenchyma, the cycles of the flow of air through the bronchioles and the transport of dissolved gases through the vasculature. 49 Given the highly complex nature of the human lung, the implementation of such mathematical and computational models can make significant demands on computing resources. A lasting concern regarding the application of mathematical modelling to medicine is ensuring the models give accurate predictions. Part of the difficulty is that the science of tissue engineering is complex and poorly understood, hence the mechanisms used to construct the models may not be accurate. Mathematical and computational models must be closely informed by experiments to obtain accurate values of model parameters and to ensure rigorous model validation.
Concluding remarks
This review has presented a summary of previous and current research in the development of bioartificial lungs, has explained fundamental scientific and technical hurdles to be overcome and has highlighted research avenues likely to contribute to the ultimate goal of producing a fully functional bioengineered replacement for the human lung.
There are several key areas of research that need further development to achieve this goal. There is the problem of being able to recreate the natural architecture and material properties of the native lung so as to obtain a scaffold with sufficient gas exchange capabilities, while providing an appropriate substrate for attachment and proliferation of cells. There is also the question of precisely what kinds of cells, and in what numbers, are sufficient to ensure that the bioartificial lung remains functional and viable within the patient.
There is the problem of creating an effective source of the large numbers of differentiated cells required for the seeding; hESCs hold much promise yet further understanding of the mechanisms of stem cell differentiation are required to harness their full potential. Safety and ethical concerns also need to be addressed before hESCs can be accepted for use in the bioartificial lung. Extensive pre-clinical testing using small and large animal models is necessary. Clinical trials must adhere to strict ethical guidelines and involve the well-informed consent of volunteer patients.
A fundamental milestone in the development of the bioartificial lung will be the successful clinical implantation of a functional reseeded donor lung. Because of the shortage of human donors, tissueengineered lungs will eventually require the use of biological scaffolds of animal origin or completely artificial scaffolds. An important parallel development will be the clinical success of the wearable bioartificial lung, i. e. a miniaturized ECMO device with an artificial oxygenator seeded with lung cells, providing longer term support for patients awaiting transplantation.
The achievement of these clinically relevant milestones, and the ultimate successful development of the bioartificial lung, will require advances across a broad range of disciplines including cell biology, materials science, engineering and mathematics. The research leading to this goal will inform, and be informed by, parallel developments in the tissue engineering of other complex organs. 50, 51 What seemed like science fiction only a few years ago seems now on the way to becoming reality. Success will mean surmounting the challenge posed by the increasing incidence of end-stage lung disease in the world.
